
Sandra Villegas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1746253/publications.pdf Version: 2024-02-01



SANDRA VILLECAS

#	Article	IF	CITATIONS
1	Mouse Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 57, 1171-1183.	1.2	201
2	Evidence for a Two-State Transition in the Folding Process of the Activation Domain of Human Procarboxypeptidase A2. Biochemistry, 1995, 34, 15105-15110.	1.2	99
3	Favourable native-like helical local interactions can accelerate protein folding. Folding & Design, 1997, 2, 23-33.	4.5	92
4	Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease. Neural Regeneration Research, 2022, 17, 1666.	1.6	87
5	Stabilization of proteins by rational design of α-helix stability using helix/coil transition theory. Folding & Design, 1996, 1, 29-34.	4.5	83
6	Early Kinetics of Amyloid Fibril Formation Reveals Conformational Reorganisation of Initial Aggregates. Journal of Molecular Biology, 2007, 366, 1351-1363.	2.0	60
7	Analysis of the activation process of porcine procarboxypeptidase B and determination of the sequence of its activation segment. Biochemistry, 1991, 30, 4082-4089.	1.2	50
8	Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease. MAbs, 2013, 5, 665-864.	2.6	48
9	Aggregated Electronegative Low Density Lipoprotein in Human Plasma Shows a High Tendency toward Phospholipolysis and Particle Fusion. Journal of Biological Chemistry, 2010, 285, 32425-32435.	1.6	46
10	Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding. Current Opinion in Lipidology, 2012, 23, 479-486.	1.2	41
11	Novel Phospholipolytic Activities Associated with Electronegative Low-Density Lipoprotein Are Involved in Increased Self-Aggregation. Biochemistry, 2008, 47, 8186-8194.	1.2	40
12	An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway. Biochemical Journal, 2011, 437, 25-34.	1.7	36
13	A <i>β</i> -Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Reviews in Molecular Medicine, 2016, 18, e13.	1.6	34
14	Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories, 2016, 15, 166.	1.9	32
15	High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level. Journal of Lipid Research, 2009, 50, 446-455.	2.0	31
16	Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils. Protein Science, 2015, 24, 1829-1840.	3.1	31
17	Influence of Aggregation Propensity and Stability on Amyloid Fibril Formation As Studied by Fourier Transform Infrared Spectroscopy and Two-Dimensional COS Analysis. Biochemistry, 2009, 48, 10582-10590.	1.2	28
18	Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation. FASEB Journal, 2015, 29, 1688-1700.	0.2	25

SANDRA VILLEGAS

#	Article	IF	CITATIONS
19	Production of an anti-AÎ ² antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect. PLoS ONE, 2017, 12, e0181480.	1.1	25
20	Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid \hat{l}^2 antibody fragment. MAbs, 2013, 5, 660-664.	2.6	24
21	Aβ-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-Aβ single chain variable fragment in combination with an apoE mimetic peptide. Molecular and Cellular Neurosciences, 2018, 89, 49-59.	1.0	21
22	The Role of Apolipoprotein E Isoforms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 68, 459-471.	1.2	21
23	2D-NMR reveals different populations of exposed lysine residues in the apoB-100 protein of electronegative and electropositive fractions of LDL particles. Journal of Lipid Research, 2010, 51, 1560-1565.	2.0	20
24	Protein structures in Alzheimer's disease: The basis for rationale therapeutic design. Archives of Biochemistry and Biophysics, 2015, 588, 1-14.	1.4	20
25	Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-β Burden. Journal of Alzheimer's Disease, 2019, 70, 1069-1091.	1.2	18
26	Differential effects of apoE and apoJ mimetic peptides on the action of an anti-AÎ ² scFv in 3xTg-AD mice. Biochemical Pharmacology, 2018, 155, 380-392.	2.0	17
27	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer's Disease is Affected by AÎ2-ImmunoTherapy and Cognitive Stimulation. Pharmaceutics, 2020, 12, 944.	2.0	17
28	Protein secondary structure and stability determined by combining exoproteolysis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Journal of Mass Spectrometry, 2002, 37, 974-984.	0.7	16
29	Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency. MAbs, 2013, 5, 678-689.	2.6	16
30	Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication, 2016, 8, 025001.	3.7	15
31	An Intracellular Amyloid-β/AβPP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 1079-1096.	1.2	15
32	Comparative Analysis of the Sequences and Three-Dimensional Models of Human Procarboxypeptidases A1, A2 and B. Biological Chemistry, 1998, 379, 149-156.	1.2	13
33	Progression of Alzheimer's disease and effect of scFvâ€h3D6 immunotherapy in the 3xTgâ€AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy. NMR in Biomedicine, 2020, 33, e4263.	1.6	13
34	Pancreatic Procarboxypeptidases: Their Activation Processes Related to the Structural Features of the Zymogens and Activation Segments. Biological Chemistry Hoppe-Seyler, 1992, 373, 387-392.	1.4	12
35	Understanding the contribution of disulfide bridges to the folding and misfolding of an antiâ€Aβ scFv. Protein Science, 2017, 26, 1138-1149.	3.1	12
36	Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides. PLoS ONE, 2017, 12, e0188191.	1.1	12

SANDRA VILLEGAS

#	Article	IF	CITATIONS
37	Expression of heat-labile enterotoxin genes is under cyclic AMP control inEscherichia coli. Current Microbiology, 1990, 20, 83-90.	1.0	11
38	The Interconversion between a Flexible β-Sheet and a Fibril β-Arrangement Constitutes the Main Conformational Event during Misfolding of PSD95-PDZ3 Domain. Biophysical Journal, 2012, 103, 738-747.	0.2	11
39	A thermodynamic study of the third PDZ domain of MAGUK neuronal protein PSD-95 reveals a complex three-state folding behavior. Biophysical Chemistry, 2014, 185, 1-7.	1.5	11
40	Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 1302-1316.	1.4	10
41	Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice. International Journal of Molecular Sciences, 2020, 21, 6630.	1.8	10
42	Common features in the unfolding and misfolding of PDZ domains and beyond: the modulatory effect of domain swapping and extra-elements. Scientific Reports, 2016, 6, 19242.	1.6	9
43	The chondroitin sulfate/dermatan sulfate 4-O-endosulfatase from marine bacterium Vibrio sp FC509 is a dimeric species: Biophysical characterization of an endosulfatase. Biochimie, 2016, 131, 85-95.	1.3	9
44	Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment. PLoS ONE, 2019, 14, e0217793.	1.1	9
45	Aβ immunotherapy for Alzheimer's disease: where are we?. Neurodegenerative Disease Management, 2016, 6, 179-181.	1.2	8
46	Towards the improvement in stability of an anti-AÎ ² single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 167-175.	1.4	8
47	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. Current Opinion in Chemical Engineering, 2018, 19, 59-67.	3.8	8
48	The Impact of Extra-Domain Structures and Post-Translational Modifications in the Folding/Misfolding Behaviour of the Third PDZ Domain of MAGUK Neuronal Protein PSD-95. PLoS ONE, 2014, 9, e98124.	1.1	8
49	Low-density lipoprotein aggregation is inhibited by apolipoprotein J-derived mimetic peptide D-[113–122]apoJ. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158541.	1.2	7
50	Principal Component and Cluster Analysis of Morphological Variables Reveals Multiple Discrete Sub-phenotypes in Weaver Mouse Mutants. Cerebellum, 2013, 12, 406-417.	1.4	6
51	Prospective Therapies for Alzheimer Disease: Biomarkers, Clinical Trials and Preclinical Research. , 2016, , 114-191.		3
52	The isolated N terminus of Ring1B is a well-folded, monomeric fragment with native-like structure. Protein Engineering, Design and Selection, 2014, 27, 1-11.	1.0	2
53	Production of Therapeutic Single-Chain Variable Fragments (ScFv) in Pichia pastoris. Methods in Molecular Biology, 2022, 2313, 151-167.	0.4	2
54	Cerebellar cortex development in the weaver condition presents regional and age-dependent abnormalities without differences in Purkinje cells neurogenesis. Acta Neurobiologiae Experimentalis, 2016, 76, 53-65.	0.4	2

SANDRA VILLEGAS

#	Article	IF	CITATIONS
55	Prediction of a new class of RNA recognition motif. Journal of Molecular Modeling, 2011, 17, 1863-1875.	0.8	1
56	Apolipoprotein J mimetic peptide [113–122]apoj decreases weight gain in LDLR-KO mice under atherogenic diet by decreasing fat accumulation. Atherosclerosis, 2017, 263, e71.	0.4	1
57	Modified Forms of LDL in Plasma. , 0, , .		0
58	Alzheimer's disease: New therapeutic strategies. Medicina ClÃnica (English Edition), 2015, 145, 76-83.	0.1	0
59	Apolipoprotein J protects against LDL aggregation. Atherosclerosis, 2015, 241, e124.	0.4	0
60	Apolipoprotein J Mimetic Peptide D-[113–122]Apoj Retard Atherosclerosis In Ldlr-Ko Mice Under Atherogenic Diet By Improving Hdl Function And Decreasing Ldl Aggregability. Atherosclerosis, 2019, 287, e200-e201.	0.4	0
61	M.461 Impaired affinity binding of electronegative LDL (LDL(\$minus;)) to the LDL receptor (LDLR). Relationship with APOB structure, non-esterified fatty acids (NEFA) and lysophosphatidylcholine (LPC) content. Atherosclerosis, 2004, 5, 107.	0.4	0